natgillin/translations-raw huggingface dataset:
These findings are not necessarily indicative of a potential for functional changes in humans.
Ti izsledki ne pomenijo nujno možnostiza funkcionalne spremembe pričloveku.
It is particularly important to try to ensure that maximal plasma levels are achieved in patients infected with Aspergillus (see sections 4.2 and 5.2 on recommended dose regimens and the effects of food on absorption).
Še posebej pomembno je, da skušate zagotoviti doseganje največje plazemske koncentracije pri bolnikih, okuženih z Aspergillusom (glejte poglavji 4.2 in 5.2 o priporočenih režimih odmerjanja in učinkih hrane na absorpcijo).
H-1045 Budapest HUNGARY
H-1045 Budimpešta Madžarska
H-1045 Budapest Hungary
H-1045 Budimpešta MADŽARSKA
- Do not use this medicine after the expiry date which is stated on the label.
- Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden naovojnini.
Clinical outcomes were compared with those in an external control group derived from a retrospective review of medical records.
Klinične izide so primerjali z izidi zunanje kontrolneskupine, ki so jih dobilina osnovi retrospektivnega pregleda zdravstvene dokumentacije.
Epidemiological Cut-off (ECOFF) Values for Aspergillus spp.
Epidemiološke mejnevrednosti (ECOFF) za Aspergillus spp.
PHARMACEUTICAL FORM AND CONTENTS Oral suspension
FARMACEVTSKA OBLIKA IN VSEBINA peroralna suspenzija
The safety and efficacy of posaconazole in children aged below 18 years have not been established.
Varnost in učinkovitost posakonazola pri otrocih, mlajših od 18 let, nista ugotovljeni.
Steady-state is attained following 7 to 10 days of multiple-dose administration.
Stanjedinamičnegaravnovesja je doseženo po 7 do 10 dneh dajanja večkratnih odmerkov.
Clinical success rate was defined as the number of cases assessed as having a clinical response (cure or improvement) divided by the total number of cases eligible for analysis
Kliničnauspešnost je bila opredeljena kot število primerov, pri katerih so ocenili pozitiven klinični odziv (ozdravitev ali izboljšanje stanja), deljeno s skupnim številom primerov, ki so bili primerni za analizo
fluconazole, itraconazole or voriconazole.
flukonazol, itrakonazol ali vorikonazol.
The filled and sealed bottle is packed into a carton along with a graduated polystyrene spoon (2.5 mL and 5 mL) for dispensing and administration of the suspension.
Napolnjena in zaprta steklenička je pakirana v škatli skupaj z označeno polistirensko žličko (z oznakama 2,5 ml in 5 ml) za odmerjanje in aplikacijo suspenzije.
Renal clearance is a minor elimination pathway, with 14 % of the radiolabelled dose excreted in urine (< 0.2 % of the radiolabelled dose is parent compound).
Ledvični očistek je manj pomembna pot izločanja;v urinu se izloči14 % radioaktivnooznačenega odmerka (< 0,2 % radioaktivno označenega odmerka predstavlja matična spojina).
The oral suspension must be shaken well before use.
Način uporabe za peroralno uporabo Peroralno suspenzijo je treba pred uporabo dobro pretresti.
Clinical success rate at Day 14 Clinical success rate 4 weeks after end of treatment
Odstotekklinične uspešnostina 14. dan Odstotekklinične uspešnosti4 tedne po koncu zdravljenja
This medicine contains less than 1 mmol sodium (23 mg) per 5 mL of suspension, that is to say essentially ‘sodium-free'.
To zdravilo vsebuje manj kot 1 mmol natrija (23 mg) v 5 ml suspenzije, kar v bistvu pomeni, da je »brez natrija«.
The external control group included 86 patients treated with available therapy (as above) mostly at the same time and at the same sites as the patients treated with posaconazole.
V zunanjikontrolni skupini je bilo 86 bolnikov,zdravljenih z razpoložljivimizdravili(kot navedeno zgoraj),večinoma ob istem času in na istih mestih kot bolniki,
Posaconazole is slowly absorbed and slowly eliminated with a large apparent volume of distribution (1,774 litres) and is highly protein bound (> 98 %), predominantly to serum albumin.
Posakonazolsepočasi absorbira in počasi izloča, z velikim navideznim porazdelitvenim volumnom(1.774 litrov) in je v veliki meri vezan na beljakovine (> 98 %), predvsem na serumski albumin.
The primary efficacy variable was the clinical success rate (defined as cure or improvement) after 14 days of treatment.
Primarni parameter učinkovitosti je bilodstotek klinične uspešnosti(opredeljena kot ozdravitev ali izboljšanjestanja)po14 dneh zdravljenja.
The ECOFF values for posaconazole, which distinguish the wild type population from isolates with acquired resistance, have been determined by EUCAST methodology.
ECOFF vrednosti za posakonazol, ki razlikujejopopulacijo divjega tipa od izolatovs pridobljenoodpornostjo, so bile določene po metodologijiEUCAST.
Food The absorption of posaconazole is significantly increased by food (see sections 4.2 and 5.2).
Absorpcija posakonazola se bistveno poveča s hrano (glejte poglavji 4.2 in 5.2).
- If you have any suspension left in a bottle more than 30 days after it was first opened, you should not use this medicine.
- Čevamveč kot 30 dni po prvem odprtju stekleničke vnjejostane še nekaj suspenzije, tegazdravila ne smete več uporabljati.
If you take more Posaconazole AHCL than you should If you are concerned that you may have taken too much, contact your doctor or healthcare professional immediately.
Če ste vzeli večji odmerek zdravila Posakonazol AHCL, kot bi smeli Če vas skrbi, da ste morda zaužili preveč zdravila, nemudoma pokličite zdravnika ali zdravstvenegadelavca.
New diagnosis of acute myelogenous leukaemia was the most common underlying condition (435/602, [72 %]).
Najpogostejša osnovna bolezen je bilana novo diagnosticirana akutna mieloična levkemija (435/602, [72%]).
There is no information on the effect of alcohol on posaconazole."
Ni podatkov o vplivu alkohola na posakonazol.
LIST OF EXCIPIENTS Contains glucose.
SEZNAM POMOŽNIH SNOVI Vsebuje glukozo.
Please make sure you tell your doctor about all the medicines you are taking (prescribed or non-prescribed).
Zdravniku morate zato povedati za vsa zdravila, ki jih jemljete (tako za zdravila, ki ste jih dobili na recept, kot za takšna,ki ste jih dobili brez recepta).
Controla Proportion (%) of patients with proven/probable Aspergillosis On-treatment periodb
Kontrolnaskupinaa Odstotek (%) bolnikov z dokazano oziroma verjetno aspergilozo Obdobjezdravljenjab
There are currently insufficient data to set clinical breakpoints for Aspergillus spp.
Trenutnoni dovolj podatkov za določitev kliničnih mejnih vrednosti za Aspergillus spp.
World Trade Center, Moll de Barcelona s/n, Edifici Est, 6a planta, Barcelona, 08039 Barcelona, Spain
World Trade Center, Moll de Barcelona s/n, Edifici Est, 6a planta, Barcelona, 08039 Barcelona, Španija
The following medicines may decrease the effectiveness of Posaconazole AHCL by decreasing the amount of Posaconazole AHCL in the blood: - rifabutin and rifampicin (used to treat certain infections).
Naslednja zdravila lahko zmanjšajo učinkovitost zdravila Posakonazol AHCL, ker zmanjšajo njegovo količino v krvi: - rifabutin in rifampicin (uporabljata se za zdravljenje določenih okužb).
EUCAST ECOFF values: - Aspergillus flavus: 0.5 mg/L - Aspergillus fumigatus: 0.25 mg/L - Aspergillus nidulans: 0.5 mg/L - Aspergillus niger: 0.5 mg/L - Aspergillus terreus: 0.25 mg/L
EUCAST ECOFF vrednosti: - Aspergillusflavus: 0,5mg/l - Aspergillus fumigatus: 0,25mg/l - Aspergillus nidulans: 0,5mg/l - Aspergillusniger: 0,5mg/l - Aspergillusterreus: 0,25mg/l
- efavirenz and fosamprenavir used to treat HIV infection.
- efavirenzinfosamprenavir,kise uporabljata za zdravljenje okužbe s HIV.
4.5 Interaction with other medicinal products and other forms of interaction
4.5 Medsebojno delovanje z drugimi zdravili
Administration of other azoles has been associated with increases in digoxin levels.
Uporaba drugih azolov je bila povezana s povečanjemkoncentracij digoksina.
Discard after 30 days of opening.
Zavrzite 30 dni po odprtju.
Prophylaxis of Invasive Fungal Infections (IFIs) (Studies 316 and 1899) Two randomised, controlled prophylaxis studies were conducted among patients at high risk for developing invasive fungal infections.
Profilaksa invazivnih glivnih okužb (študiji 316 in 1899) Opravljeni sta bili dve randomizirani, kontrolirani študiji profilakse pri bolnikih z velikim tveganjem za pojavinvazivnih glivnih okužb.
Additionally, twelve patients 13-17 years of age received posaconazole oral suspension 600 mg/day for prophylaxis of invasive fungal infections (Studies 316 and 1899).
Poleg tega je dvanajst bolnikov, starih od 13 do 17 let, prejemalo peroralno suspenzijo posakonazola v odmerku 600 mg/dan za profilakso invazivnih glivnih okužb (študiji316in 1899).
In Study 316, overall mortality was similar (POS, 25 %; FLU, 28 %); however, the proportion of IFIrelated deaths was significantly lower in the POS group (4/301) compared with the FLU group (12/299; P= 0.0413).
Vštudiji316jebila celokupna umrljivost podobna (POS 25 %, FLU 28 %), vendar je bil odstotek zinvazivno glivno okužbo povezanih smrtiv skupini s POS značilno manjši (4/301) kot vskupini sFLU (12/299, p = 0,0413).
- medicines used to decrease stomach acid such as cimetidine and ranitidine or omeprazole and similar medicines that are called proton pump inhibitors.
- zdravila, ki se uporabljajo za zmanjševanje količine želodčne kisline, kot so cimetidin in ranitidin ali omeprazol ter podobna zdravila, ki jih imenujemo zaviralci protonske črpalke.
Among eighteen patients who were intolerant or had infections refractory to amphotericin B or itraconazole, seven patients were classed as responders.
Med osemnajstimibolniki, ki niso prenašaliamfotericina B ali itrakonazola ali ki so imeli okužbe, odporne na amfotericin B ali itrakonazol, so jih sedem uvrstili med odzivne na zdravljenje.
Most of the cases of aspergillosis were considered to be refractory to prior therapy in both the posaconazole group (88 %) and in the external control group (79 %).
Večinaprimerovaspergiloze jeveljala za odporne na predhodno zdravljenje tako v skupini,kijeprejemalaposakonazol(88 %), kot v zunanji kontrolni skupini (79 %).
Pharmacokinetic modeling with an oral tablet formulation suggests that patients weighing greater than 120 kg may have lower posaconazole exposure.
Farmakokinetično modeliranje z obliko peroralnih tablet kaže, da je lahko izpostavljenost posakonazolu manjša pri bolnikih, ki tehtajo več kot 120 kg.
Patients who develop abnormal liver function tests during Posaconazole AHCLtherapy must be routinely monitored for the development of more severe hepatic injury.
Bolnike, pri katerih se med zdravljenjem z zdravilom Posakonazol AHCL pojavijo nenormalni izvidi jetrnih testov, je treba rutinsko spremljati glede nastanka hujše poškodbe jeter.
As observed with other azole antifungal agents, these effects on reproduction were considered to be due to a treatment-related effect on steroidogenesis.
Tako kot pri drugih azolskih antimikotikih so ti učinki na razmnoževanješteliza posledico z zdravljenjempovezanega učinka na steroidogenezo.
See “Other medicines and Posaconazole AHCL” below for more information including information on other medicines which may interact with Posaconazole AHCL.
Glejte"DrugazdravilainzdraviloPosakonazol AHCL"(spodaj) za več informacij, vključno z informacijami odrugih zdravilih, ki lahko medsebojno delujejo z zdravilom Posakonazol AHCL.
In Study 1899, a significant decrease in all cause mortality in favour of posaconazole was observed [POS 49/304 (16 %) vs. FLU/ITZ 67/298 (22 %) p= 0.048].
Vštudiji1899so značilno manjšo celokupno umrljivost zaradivsehvzrokovopazili v skupini, ki jeprejemala posakonazol [POS 49/304 (16 %) v primerjavi s FLU/ITZ67/298 (22 %), p = 0,048].
Increased systolic and arterial blood pressures (up to 29 mm-Hg) were seen in rats and monkeys at systemic exposures 1.4-fold and 4.6-fold greater, respectively, than those achieved with the human therapeutic doses.
Zvišan sistolični in arterijski krvni tlak (do 29 mmHg) so opažali pri podganah oz. opicahpri sistemskih izpostavljenostih, ki so bile 1,4-krat oz. 4,6-krat večje od izpostavljenosti, doseženih sterapevtskimiodmerkipričloveku.
flatulence, constipation, anorectal discomfort
flatulenca, konstipacija, anorektalno nelagodje
Posaconazole increased the Cmax and AUC of rifabutin by 31 % and 72 %, respectively.
Rifabutin Posakonazolje povečal Cmaxrifabutina za 31%in AUC rifabutina za 72 %.
A measuring spoon is provided with each bottle for measuring 2.5 and 5 mL doses of the oral suspension.
Vsaki steklenički je priložena odmerna žlička za odmerjanje 2,5 in 5ml peroralne suspenzije.
Posaconazole is a potent inhibitor of CYP3A4.
Posakonazol je močan zaviralec CYP3A4.
Posaconazole AHCL must not be administered with medicinal products that are substrates for CYP3A4 and are known to prolong the QTc interval (see sections 4.3 and 4.5).
Zdravila Posakonazol AHCL se ne sme uporabljati skupaj z zdravili, ki so substrati CYP3A4 in za katere je znano, da podaljšajo interval QTc (glejte poglavji 4.3 in 4.5).
- a “statin” such as simvastatin, atorvastatin or lovastatin used to treat high cholesterol.
- katerega od statinov, na primer simvastatina, atorvastatina ali lovastatina, ki se uporabljajozazdravljenje visokega holesterola.
Posaconazole tablets are the preferred formulation to optimize plasma concentrations and generally provide higher plasma drug exposures than posaconazole oral suspension.
Posakonazol v obliki tablet jeprimernejša oblika za optimiziranje plazemske koncentracije in na splošno zagotavlja večjo plazemsko izpostavljenost zdravilu kot peroralna suspenzija posakonazola.
- Candida albicans: S ≤0.06 mg/L, R >0.06 mg/L - Candida tropicalis: S ≤0.06 mg/L, R >0.06 mg/L - Candida parapsilosis: S ≤0.06 mg/L, R >0.06 mg/L
Mejnevrednosti EUCAST MIC za posakonazol [občutljivi(S-susceptible); odporni (R-resistant)]: - Candida albicans:S≤0,06 mg/l, R> 0,06 mg/l - Candida tropicalis:S≤0,06 mg/l, R> 0,06 mg/l - Candida parapsilosis:S≤0,06 mg/l, R> 0,06 mg/l
• If you have any further questions, ask your doctor, pharmacist or nurse.
• Če imate dodatna vprašanja, se posvetujte z zdravnikom,farmacevtomali medicinsko sestro.
electrolyte imbalance, anorexia, decreased appetite, hypokalaemia, hypomagnesaemia
neravnovesje elektrolitov, anoreksija, zmanjšanje apetita,hipokaliemija, hipomagneziemija
For patients with acute myelogenous leukemia or myelodysplastic syndromes, prophylaxis with Posaconazole AHCL should start several days before the anticipated onset of neutropenia and continue for 7 days after the neutrophil count rises above 500 cells per mm3.
Pri bolnikih z akutno mieloično levkemijo ali mielodisplastičnimi sindromi je treba profilakso z zdravilom Posakonazol AHCL začeti več dni pred pričakovanimpojavomnevtropenije innajtrajaše 7 dnipozvečanju števila nevtrofilcev nad
Concomitant use of posaconazole and rifabutin should be avoided unless the benefit to the patient outweighs the risk (see also above regarding the effect of rifabutin on plasma levels of posaconazole).
Sočasniuporabiposakonazola in rifabutina se je treba izogibati, razen če korist za bolnika odtehta tveganje (glejte zgoraj za učinke rifabutina na plazemsko koncentracijo posakonazola).
Effects of posaconazole on other medicinal products
Vpliviposakonazola na druga zdravila
Posaconazole is absorbed with a median tmax of 3 hours (fed patients).
Absorpcija Posakonazolse absorbira z medianovrednostjo tmax 3 ure (nahranjeni bolniki).
Tabulated list of adverse reactions Within the organ system classes, adverse reactions are listed under headings of frequency using the following categories: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥ 1/10,000 to <1/1,000); very rare (<1/10,000); not known.
V okviru organskih sistemovso neželeni učinki navedeniz naslednjimi kategorijami pogostnosti: zelopogosti (≥1/10), pogosti (od ≥1/100 do < 1/10), občasni (od ≥1/1.000 do < 1/100), redki (od
Do not adapt your dose yourself before consulting your doctor or change your treatment regime.
Brezposvetovanja zzdravnikom si odmerka ali režima zdravljenja ne smete spreminjati sami.
The effect of posaconazole on CYP3A4 substrates in patients might be somewhat lower than that observed in healthy volunteers, and is expected to be variable between patients due to the variable posaconazole exposure in patients.
Učinek posakonazola na substrate CYP3A4 je lahko pri bolnikih nekolikomanjši kot pri zdravih prostovoljcih in mogoče je pričakovati, da se od bolnika dobolnika razlikuje zaradi različne stopnje izpostavljenosti posakonazolu.
Posaconazole had no effect on fertility of male rats at doses up to 180 mg/kg (1.7 times the 400 mg twice daily regimen based on steady-state plasma concentrations in healthy volunteers) or female rats at a dose up to 45 mg/kg (2.2 times the 400-mg twice daily regimen).
Posakonazol ni vplival na plodnost podganjih samcev v odmerkih do 180 mg/kg (1,7-krat 400 mg režim dvakrat na dan, ki temelji na plazemskih koncentracijah v stanju dinamičnega ravnovesja pri zdravih prostovoljcih) ali podganjih samic v odmerku do 45 mg/kg (2,2-krat 400 mg režim dvakrat na dan).
As HIV protease inhibitors are CYP3A4 substrates, it is expected that posaconazole will increase plasma levels of these antiretroviral agents.
Zaviralci proteaze HIV so substrati CYP3A4, zato se pričakuje, da bo posakonazol povečal plazemskokoncentracijo teh protiretrovirusnih zdravil.
Posaconazole AHCL can increase the amount of these medicines in the blood which may lead to a severe decrease in blood flow to your fingers or toes and could cause damage to them.
Zdravilo Posakonazol AHCL lahko poveča koncentracijo teh zdravilv krvi; to lahko zelo zmanjša dotok krvi v prste rok in nog in lahko povzroči njihovo okvaro.
Posaconazole AHCL contains approximately 1.75g of glucose per 5mLof suspension.
Zdravilo Posakonazol AHCL vsebuje približno 1,75 g glukoze na 5 ml suspenzije.
Overall efficacy of posaconazole oral suspension at the end of treatment for invasive aspergillosis in comparison to an external control group
Skupna učinkovitost peroralnesuspenzije posakonazola ob koncu zdravljenjainvazivneaspergiloze v primerjavi z zunanjokontrolnoskupino Peroralnasuspenzijaposakona zola
- if you are taking: terfenadine, astemizole, cisapride, pimozide, halofantrine, quinidine, any medicines that contain “ergot alkaloids” such as ergotamine or dihydroergotamine, or a “statin” such as simvastatin, atorvastatin or lovastatin
- čejemljete:terfenadin, astemizol, cisaprid, pimozid, halofantrin, kinidin, katero koli zdravilo, ki vsebuje alkaloide ergot(na primer ergotamin ali dihidroergotamin)ali kakšen statin, naprimer simvastatin, atorvastatin ali lovastatin.
Posaconazole is also available as 100 mg gastro-resistant tablet and 300 mg concentrate for solution for infusion.
Posakonazol je na voljo tudi v obliki 100-miligramskih gastrorezistentnih tabletin 300-miligramskega koncentrata za raztopino za infundiranje.
The effect of posaconazole on sirolimus in patients is unknown, but is expected to be variable due to the variable posaconazole exposure in patients.
Učinek posakonazola na sirolimus pri bolnikih ni znan, vendar jetrebapričakovati, da jespremenljiv zaradi spremenljive izpostavljenosti posakonazolu med bolniki.
Following administration of 800 mg per day of posaconazole as a divided dose for treatment of invasive fungal infections, mean trough plasma concentrations from 12 patients 8 - 17 years of age (776 ng/mL) were similar to concentrations from 194 patients 18 - 64 years of age (817 ng/mL).
Po uporabi800 mg posakonazola na dan v deljenih odmerkih za zdravljenje invazivnih glivnih okužbje bila povprečna najmanjša plazemska koncentracija pri 12 bolnikih, starih od 8 do 17 let (776 ng/ml), podobnakotpri 194 bolnikih, starih od 18 do 64 let(817 ng/ml).
No further increases in exposure were observed when doses above 800 mg daily were administered to patients and healthy volunteers.
Pri dajanju odmerkov nad 800 mg na dan bolnikom in zdravim prostovoljcem nisoopažali nobenega nadaljnjega povečanja izpostavljenosti zdravilu.
To improve absorption of posaconazole, whenever possible it should be taken during or immediately after food or a nutritional drink (see section 3 “How to take Posaconazole AHCL”).
Zdravilo Posakonazol AHCL skupaj s hrano in pijačo Da se izboljša absorpcija posakonazola ga, kadar koli je le mogoče, vzemite med ali takoj po jedi ali zaužitju prehranskega dopolnila v obliki napitka (glejte poglavje 3 “Kako jemati zdravilo Posakonazol AHCL”).
The primary packaging is an amber glass bottle (Type III) closed with a child-resistant and tamper evident polypropylene cap.
Primarna ovojnina je steklenička iz rjavega stekla (tipa III), zaprta z za otrokevarno polipropilenskozaporko, ki je ni mogoče odpreti brez vidnih znakov odprtja.
The pharmacokinetics of posaconazole are linear following single and multiple dose administration of up to 800 mg when taken with a high fat meal.
Farmakokinetikaposakonazola je linearna po enkratnem in večkratnem dajanju odmerkov do 800 mg,
Alternatively, patients who can tolerate food or a nutritional supplement may take 400 mg (10 mL) twice a day during or immediately following a meal or nutritional supplement.
200 mg(5 ml) štirikrat na dan. Bolniki, ki prenašajo hrano aliprehranske dodatke, lahko vzamejo 400 mg (10ml) dvakrat na danmed ali takoj po jedi ali prehranskem dodatku.
If you develop severe diarrhoea or vomiting (being sick) while taking Posaconazole AHCL, talk to your doctor, pharmacist or nurse straight away, as this may stop it from working properly.
Če se med jemanjem zdravila Posakonazol AHCL pojavita huda driska ali bruhanje (slabost), se takoj posvetujte z zdravnikom, farmacevtom ali medicinsko sestro, kajti lahko preprečita pravilno delovanje zdravila.
Posaconazole inhibits the enzyme lanosterol 14α-demethylase (CYP51), which catalyses an essential step in ergosterol biosynthesis.
Posakonazolzaviraencimlanosterol-14α-demetilazo(CYP51),kikatalizira eno od ključnih stopenj vbiosintezi ergosterola.
Non-Interchangeability between posaconazole tablets and Posaconazole AHCL Oral Suspension The tablet and oral suspension are not to be used interchangeably due to the differences between these two formulations in frequency of dosing, administration with food and plasma drug concentration achieved.
Medsebojna nezamenljivost tablet posakonazola in Posakonazol AHCL peroralne suspenzije Tablet in peroralne suspenzije se ne sme uporabljati medsebojno zamenljivo zaradi razlik med oblikama v pogostnosti odmerjanja, razlik pri uporabi s hrano in razlik v doseganju plazemskih koncentracij zdravila.
The effect of co-administration with posaconazole on plasma levels of CYP3A4 substrates may also be variable within a patient, unless posaconazole is administered in a strictly standardised way with food, given the large food effect on posaconazole exposure (see section 5.2).
Učinek sočasne uporabe posakonazola na plazemske koncentracije substratov CYP3A4 se lahkorazlikuje tudi pri posameznembolniku, razen če prejme posakonazol na strogo standardiziran način s hrano, glede na velik vplivhrane na izpostavljenost posakonazolu (glejte poglavje 5.2).
In rabbits, posaconazole was embryotoxic at exposures greater than those obtained at therapeutic doses.
Pri kuncih je bilposakonazol embriotoksičen pri izpostavljenostih, večjih od izpostavljenosti, doseženih sterapevtskimiodmerki.
Patients were treated with posaconazole or fluconazole oral suspension (both posaconazole and fluconazole were given as follows: 100 mg twice a day for 1 day followed by 100 mg once a day for 13 days).
Bolnikeso zdravili s posakonazolom ali s peroralno suspenzijo flukonazola (tako posakonazol kot flukonazol soodmerjalinanaslednjinačin:100 mg dvakrat na dan 1 dan,potempa100 mg enkrat na dan 13 dni).
White to off-white free flowing suspension.
FARMACEVTSKA OBLIKA peroralna suspenzija bela do belkasta dobro tekoča suspenzija
In addition, posaconazole oral suspension (200 mg or 400 mg) prolonged the mean terminal half-life of midazolam from approximately 3-4 hours to 8-10 hours during co-administration.
Poleg tega jeperoralnasuspenzija posakonazola (200 mg ali 400mg) med sočasno uporabo podaljšala povprečniterminalnirazpolovničas midazolama s približno 3 do 4ure na 8 do 10 ur.